← Back to Search
Application Of Nanotechnology In Cancer Therapy And Imaging
X. Wang, Lily L. Yang, Z. Chen, D. M. Shin
Published 2008 · Materials Science, Medicine
Download PDFAnalyze on Scholarcy
Recent developments in nanotechnology have provided researchers with new tools for cancer imaging and treatment. This technology has enabled the development of nanoscale devices that can be conjugated with several functional molecules simultaneously, including tumor‐specific ligands, antibodies, anticancer drugs, and imaging probes. Since these nanodevices are 100 to 1,000‐fold smaller than cancer cells, they can be easily transferred through leaky blood vessels and interact with targeted tumor‐specific proteins both on the surface of and inside cancer cells. Therefore, their application as cancer cell‐specific delivery vehicles will be a significant addition to the currently available armory for cancer therapeutics and imaging.
This paper references
Efficacy of pegylated-liposomal doxorubicin in the treatment of AIDS-related Kaposi's sarcoma after failure of standard chemotherapy.
D. Northfelt (1997)
Albumin-bound nanoparticle paclitaxel.
W. Gradishar (2005)
Folate receptor targeted delivery of liposomal daunorubicin into tumor cells.
Sandy Ni (2002)
HPMA copolymer–anticancer drug–OV‐TL16 antibody conjugates. II. Processing in epithelial ovarian carcinoma cells in vitro
V. Omelyanenko (1998)
Doxorubicin Encapsulated in Liposomes Containing Surface‐Bound Polyethylene Glycol: Pharmacokinetics, Tumor Localization, and Safety in Patients with AIDS‐Related Kaposi's Sarcoma
D. Northfelt (1996)
Nanocarriers: promising vehicle for bioactive drugs.
M. Rawat (2006)
Intraoperative sentinel lymph node mapping of the lung using near-infrared fluorescent quantum dots.
E. Soltesz (2005)
Targeted therapies for cancer 2004.
J. Ross (2004)
Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties.
S. Moghimi (2003)
Liposomes designed to avoid the reticuloendothelial system.
D. Papahadjopoulos (1990)
The emerging nanomedicine landscape
Volker Wagner (2006)
Exploiting the hallmarks of cancer: the future conquest of breast cancer.
G. Sledge (2003)
Modification of cyclosporin A and conjugation of its derivative to HPMA copolymers.
Z. Lu (2001)
Phase I-II study of pegylated liposomal cisplatin (SPI-077) in patients with inoperable head and neck cancer.
K. Harrington (2001)
Phase I and pharmacokinetic study of DE-310 in patients with advanced solid tumors.
O. Soepenberg (2005)
Improved Therapeutic Responses in a Xenograft Model of Human B Lymphoma (Namalwa) for Liposomal Vincristine versus Liposomal Doxorubicin Targeted via Anti-CD19 IgG2a or Fab′ Fragments
P. Sapra (2004)
How can we best use structural information on P-glycoprotein to design inhibitors?
C. A. McDevitt (2007)
Improvement of MRI probes to allow efficient detection of gene expression.
D. Högemann (2000)
Phase I and pharmacokinetic trial of AP5346, a DACH–platinum–polymer conjugate, administered weekly for three out of every 4 weeks to advanced solid tumor patients
M. Campone (2006)
Drug delivery systems: enter ing the mainstream
TM Allen (2004)
Uptake of dextran‐coated monocrystalline iron oxides in tumor cells and macrophages
A. Moore (1997)
Neutrophil Transepithelial Migration: Evidence for Sequential, Contact-Dependent Signaling Events and Enhanced Paracellular Permeability Independent of Transjunctional Migration1
H. Edens (2002)
Biodistribution of fluoresceinated dextran using novel nanoparticles evading reticuloendothelial system.
U. Gaur (2000)
Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer.
W. Gradishar (2005)
A Phase 2 trial of the liposomal DACH platinum L-NDDP in patients with therapy-refractory advanced colorectal cancer
T. Dragovich (2006)
pH-sensitive liposomes: possible clinical implications.
M. Yatvin (1980)
In vivo high resolution three-dimensional imaging of antigen-specific cytotoxic T-lymphocyte trafficking to tumors.
M. Kircher (2003)
Recognition and clearance of methoxypoly(ethyleneglycol)2000-grafted liposomes by macrophages with enhanced phagocytic capacity. Implications in experimental and clinical oncology.
P. Laverman (2001)
Prodrug chemotherapeutics bypass p-glycoprotein resistance and kill tumors in vivo with high efficacy and target-dependent selectivity
V. Guillemard (2004)
Near-infrared optical imaging of integrin αvβ3 in human tumor xenografts
W. Wang (2004)
Targeting of stealth liposomes to erbB-2 (Her/2) receptor: in vitro and in vivo studies.
D. Goren (1996)
Efficacy of liposomes and hyperthermia in a human tumor xenograft model: importance of triggered drug release.
G. Kong (2000)
Intracranial Thermotherapy using Magnetic Nanoparticles Combined with External Beam Radiotherapy: Results of a Feasibility Study on Patients with Glioblastoma Multiforme
K. Maier-Hauff (2006)
HPMA copolymer-anticancer drug-OV-TL16 antibody conjugates. 1. influence of the method of synthesis on the binding affinity to OVCAR-3 ovarian carcinoma cells in vitro.
V. Omelyanenko (1996)
Quantum dot bioconjugates for ultrasensitive nonisotopic detection.
W. C. Chan (1998)
Peptide-labeled near-infrared quantum dots for imaging tumor vasculature in living subjects.
W. Cai (2006)
Factors governing the in vivo tissue uptake of transferrin-coupled polyethylene glycol liposomes in vivo.
H. Hatakeyama (2004)
Biopharmaceutics of liposomal interleukin 2, oncolipin.
M. Neville (2000)
A Phase I and Pharmacological Study of the Platinum Polymer AP5280 Given as an Intravenous Infusion Once Every 3 Weeks in Patients with Solid Tumors
J. Rademaker-Lakhai (2004)
Long-circulating (sterically stabilized) liposomes for targeted drug delivery.
T. Allen (1994)
Liposome-based drug delivery in breast cancer treatment
J. Park (2002)
Drug Delivery Systems: Entering the Mainstream
T. Allen (2004)
A Phase 2 trial of the liposomal DACH platinum LNDDP in patients with therapy-refractory advanced colorectal cancer
T Dragovich (2006)
Vascular Targeted Nanoparticles for Imaging and Treatment of Brain Tumors
G. R. Reddy (2006)
Molecular Imaging in Cancer
R. Weissleder (2006)
New technologies and directed agents for applications of cancer imaging.
M. Atri (2006)
Transport of molecules across tumor vasculature
R. Jain (2004)
The Hallmarks of Cancer
D. Hanahan (2000)
Nanoparticle and targeted systems for cancer therapy.
L. Brannon-Peppas (2004)
PIONEER: a phase III randomized trial of paclitaxel poliglumex versus paclitaxel in chemotherapy-naive women with advanced-stage non-small-cell lung cancer and performance status of 2.
K. Albain (2006)
Photonic explorers based on multifunctional nanoplatforms for biosensing and photodynamic therapy.
Y. Koo (2007)
Development of ligand-targeted liposomes for cancer therapy
C. Noble (2004)
Determination and Modeling of Kinetics of Cancer Cell Killing by Doxorubicin and Doxorubicin Encapsulated in Targeted Liposomes
R. E. Eliaz (2004)
Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery.
J. Park (2002)
Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin
Y. Matsumura (2004)
Clinical evidence of efficient tumor targetting based on single–chain Fv antibody selected from a combinatorial library
R. Begent (1996)
Quantum dot-based multiplexed fluorescence resonance energy transfer.
A. R. Clapp (2005)
Phase I and pharmacokinetic study of DE310 in patients with advanced solid tumors
O Soepenberg (2005)
A randomised phase II study of OSI-7904L versus 5-fluorouracil (FU)/leucovorin (LV) as first-line treatment in patients with advanced biliary cancers
T. Ciuleanu (2007)
Matrix metalloproteinases and tumor metastasis
E. Deryugina (2006)
Albumin-bound paclitaxel: a next-generation taxane
W. Gradishar (2006)
Nanoparticle imaging of integrins on tumor cells.
X. Montet (2006)
Effective drug delivery by PEGylated drug conjugates.
R. Greenwald (2003)
Phase II study of SPI-77 (sterically stabilised liposomal cisplatin) in advanced non-small-cell lung cancer
S. White (2006)
Near-infrared optical imaging of proteases in cancer.
U. Mahmood (2003)
Phase I Clinical and Pharmacokinetic Study of PK1 [N-(2-Hydroxypropyl)methacrylamide Copolymer Doxorubicin]: First Member of a New Class of Chemotherapeutic Agents—Drug-Polymer Conjugates
P. Vasey (1999)
Emerging implications of nanotechnology on cancer diagnostics and therapeutics
A. Cuenca (2006)
Molecular imaging of cancer using PET and SPECT.
A. Kjaer (2006)
Novel approaches for targeted cancer therapy.
V. Guillemard (2004)
Long-circulating and target-specific nanoparticles: theory to practice.
S. Moghimi (2001)
A phase I study with MAG-camptothecin intravenously administered weekly for 3 weeks in a 4-week cycle in adult patients with solid tumours
F. M. Wachters (2004)
Liposomal Drug Delivery
R. Fielding (1991)
Biodegradable long-circulating polymeric nanospheres.
R. Gref (1994)
[Micelle carrier system in clinical trial].
Y. Matsumura (2006)
Cancer nanotechnology: opportunities and challenges
M. Ferrari (2005)
Mechanism of pluronic effect on P-glycoprotein efflux system in blood-brain barrier: contributions of energy depletion and membrane fluidization.
E. Batrakova (2001)
Multifunctional polymeric micelles as cancer-targeted, MRI-ultrasensitive drug delivery systems.
N. Nasongkla (2006)
Poly(ethylene glycol) multiblock copolymer as a carrier of anti-cancer drug doxorubicin.
M. Pechar (2000)
Phase I and pharmacokinetic (PK) study of MAG-CPT (PNU 166148): a polymeric derivative of camptothecin (CPT)
D. Bissett (2004)
Magnetic resonance molecular imaging of the HER-2/neu receptor.
D. Artemov (2003)
A phase I and pharmacokinetic study of OSI-7904L, a liposomal thymidylate synthase inhibitor in combination with oxaliplatin in patients with advanced colorectal cancer
A. Clamp (2007)
Clinical trials of P-glycoprotein reversal in solid tumours.
D. Ferry (1996)
Block copolymer micelles: preparation, characterization and application in drug delivery.
G. Gaucher (2005)
Doxorubicin loaded pH-sensitive polymeric micelles for reversal of resistant MCF-7 tumor.
E. Lee (2005)
Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II Committee.
P. Vasey (1999)
Nanoparticle–aptamer bioconjugates for cancer targeting
O. Farokhzad (2006)
Polymer conjugates: nanosized medicines for treating cancer.
M. Vicent (2006)
Population pharmacokinetics in phase I drug development: a phase I study of PK1 in patients with solid tumours
A. Thomson (1999)
Effect of transvascular fluid exchange on pressure-flow relationship in tumors: a proposed mechanism for tumor blood flow heterogeneity.
P. A. Netti (1996)
Contrast‐enhanced MR imaging of liver and spleen: First experience in humans with a new superparamagnetic iron oxide
B. Hamm (1994)
Ligand-targeted liposomes for cancer treatment.
P. Sapra (2005)
Targeted drug delivery via the folate receptor.
J. Sudimack (2000)
Glycolysis inhibition for anticancer treatment
H. Pelicano (2006)
Technology evaluation: PK1, Pfizer/Cancer Research UK.
V. Bilim (2003)
Water-soluble dendritic unimolecular micelles: their potential as drug delivery agents.
M. Liu (2000)
In vivo tumor targeting and radionuclide imaging with self-assembled nanoparticles: mechanisms, key factors, and their implications.
Yong Woo Cho (2007)
Antibody targeting of doxorubicin-loaded liposomes suppresses the growth and metastatic spread of established human lung tumor xenografts in severe combined immunodeficient mice.
M. Sugano (2000)
Efficacy and safety of paclitaxel poliglumex as first-line chemotherapy in patients at high risk with advanced-stage non-small-cell lung cancer: results of a phase II study.
D. Richards (2005)
A new approach for the treatment of malignant melanoma: enhanced antitumor efficacy of an albumin-binding doxorubicin prodrug that is cleaved by matrix metalloproteinase
AM Mansour (2003)
MR molecular imaging of the Her‐2/neu receptor in breast cancer cells using targeted iron oxide nanoparticles
D. Artemov (2003)
Quantum dot bioconjugates for imaging, labelling and sensing
Igor L. Medintz (2005)
Breast MRI and 18F FDG PET/CT in the management of breast cancer.
A. Iagaru (2007)
A possible mechanism for the long-lasting antitumor effect of the macromolecular conjugate DE-310: mediation by cellular uptake and drug release of its active camptothecin analog DX-8951
Y. Ochi (2004)
Engineering S-protein fragments of bovine ribonuclease A for targeted drug delivery.
M. Backer (2002)
Iron oxide nanoparticles as magnetic resonance contrast agent for tumor imaging via folate receptor-targeted delivery.
H. Choi (2004)
Artificially engineered magnetic nanoparticles for ultra-sensitive molecular imaging
Jaehyun Lee (2007)
Assessment of normal and tumor tissue uptake of MAG-CPT, a polymer-bound prodrug of camptothecin, in patients undergoing elective surgery for colorectal carcinoma
N. Sarapa (2003)
Multispectral imaging of clinically relevant cellular targets in tonsil and lymphoid tissue using semiconductor quantum dots
Thomas J. Fountaine (2006)
Phase I clinical and pharmacokinetic study of PNU166945, a novel water-soluble polymer-conjugated prodrug of paclitaxel
J. M. Meerum Terwogt (2001)
Phase I clinical and pharmacokinetic trial of dextran conjugated doxorubicin (AD-70, DOX-OXD)
S. Danhauser-Riedl (2004)
UEA I-bearing nanoparticles for brain delivery following intranasal administration.
X. Gao (2007)
Molecular Imaging Applications in Nanomedicine
K. C. Li (2004)
Tat peptide-derivatized magnetic nanoparticles allow in vivo tracking and recovery of progenitor cells
M. Lewin (2000)
Antibody-targeted Polymer–doxorubicin Conjugates with pH-controlled Activation
K. Ulbrich (2004)
Phase I and pharmacokinetic study of MCC-465, a doxorubicin (DXR) encapsulated in PEG immunoliposome, in patients with metastatic stomach cancer.
Y. Matsumura (2004)
Phase I clinical and pharmacokinetic trial of dextran conjugated doxorubicin (AD-70, DOXOXD)
S Danhauser-Riedl (1993)
Detection of lymph node metastases by contrast‐enhanced MRI in an experimental model
P. Wunderbaldinger (2002)
Iron oxide MR contrast agents for molecular and cellular imaging
J. Bulte (2004)
A new approach for the treatment of malignant melanoma: enhanced antitumor efficacy of an albumin-binding doxorubicin prodrug that is cleaved by matrix metalloproteinase 2.
Ahmed M. Mansour (2003)
Enhanced antiproliferative activity of transferrin-conjugated paclitaxel-loaded nanoparticles is mediated via sustained intracellular drug retention.
S. Sahoo (2005)
Antitumor effect of MCC‐465, pegylated liposomal doxorubicin tagged with newly developed monoclonal antibody GAH, in colorectal cancer xenografts
T. Hamaguchi (2004)
In vivo imaging of siRNA delivery and silencing in tumors
Z. Medarova (2007)
Drug release rate influences the pharmacokinetics, biodistribution, therapeutic activity, and toxicity of pegylated liposomal doxorubicin formulations in murine breast cancer.
G. Charrois (2004)
Oncotic pressure in solid tumors is elevated.
M. Stohrer (2000)
Preclinical safety, pharmacokinetics and antitumor efficacy profile of liposome-entrapped SN-38 formulation.
A. Pal (2005)
A phase I and pharmacokinetic study of pegylated camptothecin as a 1-hour infusion every 3 weeks in patients with advanced solid malignancies.
E. Rowinsky (2003)
A Phase I Study of SPI-077 (Stealth® Liposomal Cisplatin) Concurrent with Radiation Therapy for Locally Advanced Head and Neck Cancer
D. Rosenthal (2004)
Noninvasive detection of clinically occult lymph-node metastases in prostate cancer.
M. Harisinghani (2003)
Tumor cell targeting of liposome-entrapped drugs with phospholipid-anchored folic acid-PEG conjugates.
A. Gabizon (2004)
The use of liposomal daunorubicin (DaunoXome) in acute myeloid leukemia
A. Fassas (2005)
A phase II study of liposomal lurtotecan (OSI-211) in patients with topotecan resistant ovarian cancer.
M. Seiden (2004)
Near-infrared optical imaging of integrin alphavbeta3 in human tumor xenografts.
W. Wang (2004)
Contributions of advanced proteomics technologies to cancer diagnosis
S. Ciordia (2006)
Gateways to clinical trials.
M. Bayes (2005)
Liposome-based approaches to overcome anticancer drug resistance.
C. Mamot (2003)
Tumoral distribution of long-circulating dextran-coated iron oxide nanoparticles in a rodent model.
A. Moore (2000)
In vivo cancer targeting and imaging with semiconductor quantum dots
X. Gao (2004)
FeCo/graphitic-shell nanocrystals as advanced magnetic-resonance-imaging and near-infrared agents
W. Seo (2006)
Polymer-drug conjugates: towards a novel approach for the treatment of endrocine-related cancer.
R. Duncan (2005)
Optical imaging of apoptosis as a biomarker of tumor response to chemotherapy.
Eyk A. Schellenberger (2003)
Quantitative acid hydrolysis of DE-310, a macromolecular carrier system for the camptothecin analog DX-8951f.
Y. Shiose (2007)
Hepatic drug targeting: phase I evaluation of polymer-bound doxorubicin.
L. Seymour (2002)
Molecular vehicles for targeted drug delivery.
M. Backer (2002)
Targeted liposomal drug delivery in cancer.
O. Medina (2004)
The dawning era of polymer therapeutics
R. Duncan (2003)
Iron oxide nanoparticles for sustained delivery of anticancer agents.
Tapan Jain (2005)
Molecular imaging of cancer with positron emission tomography
S. Gambhir (2002)
Mechanism of sensitization of MDR cancer cells by Pluronic block copolymers: Selective energy depletion
E. Batrakova (2001)
Liposomal encapsulated anti-cancer drugs.
R. Hofheinz (2005)
Paclitaxel Poliglumex (PPX-Xyotax) and Concurrent Radiation for Esophageal and Gastric Cancer: A Phase I Study
T. Dipetrillo (2006)
Internalizing antibodies are necessary for improved therapeutic efficacy of antibody-targeted liposomal drugs.
P. Sapra (2002)
Ligand-targeted therapeutics in anticancer therapy
T. Allen (2002)
In vivo molecular and cellular imaging with quantum dots.
X. Gao (2005)
Paclitaxel quantification in mouse plasma and tissues containing liposome-entrapped paclitaxel by liquid chromatography-tandem mass spectrometry: application to a pharmacokinetics study.
W. Guo (2005)
Crystal size and properties of superparamagnetic iron oxide (SPIO) particles.
C. Sjögren (1997)
Small-scale systems for in vivo drug delivery
David A. LaVan (2003)
Blood-Brain Barrier Carrier-Mediated Transport and Brain Metabolism of Amino Acids
W. Pardridge (2004)
Diagnostics and Therapeutics
Lois N. Magner (2005)
Liposomal drug delivery.
Allison Sd (2007)
Pharmaceutical development, quality control, stability and compatibility of a parenteral lyophilized formulation of the investigational polymer-conjugated platinum antineoplastic agent AP5346.
S. C. van der Schoot (2006)
A Phase I and Pharmacokinetic Study of Paclitaxel Poliglumex (XYOTAX), Investigating Both 3-Weekly and 2-Weekly Schedules
A. Boddy (2005)
Emerging implications of nanotechnology on
On the use of ion-pair chromatography to elucidate doxorubicin release mechanism from polyalkylcyanoacrylate nanoparticles at the cellular level.
X. Pépin (1997)
THE NEXT GENERATION OF LIPOSOME DELIVERY SYSTEMS: RECENT EXPERIENCE WITH TUMOR-TARGETED, STERICALLY-STABILIZED IMMUNOLIPOSOMES AND ACTIVE-LOADING GRADIENTS
R. Abra (2002)
Poly(L-glutamic acid)--anticancer drug conjugates.
Chun Xing Li (2002)
This paper is referenced by
Optical imaging-guided cancer therapy with fluorescent nanoparticles
S. Jiang (2009)
Elaboration and characterization of nanoliposome made of soya; rapeseed and salmon lecithins: application to cell culture.
Elmira Arab Tehrany (2012)
The use of cationic MPEG-PCL-g-PEI micelles for co-delivery of Msurvivin T34A gene and doxorubicin.
Shuai Shi (2014)
Folate-conjugated nanoparticles as a potent therapeutic approach in targeted cancer therapy
B. Bahrami (2015)
An Improved Method for Fabrication of Ag-GO Nanocomposite with Controlled Anti-Cancer and Anti-bacterial Behavior; A Comparative Study
S. Khorrami (2019)
Synthetic asymmetric lipid-like organosilanes for liposomal nanohybrid cerasomes toward potential medical applications
Zaret G. Denieva (2019)
Multimodal tumor imaging by iron oxides and quantum dots formulated in poly (lactic acid)-D-alpha-tocopheryl polyethylene glycol 1000 succinate nanoparticles.
Y. Tan (2011)
Nanoparticles in Drug Delivery and Cancer Therapy: The Giant Rats Tail
V. V. Prabhu (2011)
Delivery of nanoparticle‐complexed drugs across the vascular endothelial barrier via caveolae
Zhenjia Wang (2011)
Drug Delivery Using Nanocarriers: Indian Perspective
S. Gupta (2012)
Nanotechnology in the field of clinical oncology Klinik onkoloji alanında nanoteknoloji
M. Topçul ()
Intracellular transport of nanodiamond particles in human endothelial and epithelial cells.
K. Solarska-Ściuk (2014)
Nanooncology: The future of cancer diagnosis and therapy
A. Thakor (2013)
Cerium oxide nanoparticles in cancer
Y. Gao (2014)
Anti Wnt-1 Monoclonal Antibody’s Conjugated with Gold Nanoparticles, Induced Apoptosis on MCF-7 Breast Cancer Cell Lines
Mehdi Tayybi Azar (2019)
Inductively coupled RF heating of nano-particle for non-invasive and selective cancer cell destruction
Hyo-Chang Lee (2010)
A strategy for precision engineering of nanoparticles of biodegradable copolymers for quantitative control of targeted drug delivery.
Y. Liu (2010)
Antiproliferative effect of silver nanoparticles synthesized using amla on Hep2 cell line.
F. S. Rosarin (2013)
Current aspects of breast cancer therapy and diagnosis based on a nanocarrier approach
F. G. Praça (2017)
Folic acid and its derivatives for targeted photodynamic therapy of cancer
Nikita V. Suvorov (2017)
PD-L1 monoclonal antibody-conjugated nanoparticles enhance drug delivery level and chemotherapy efficacy in gastric cancer cells
S. Xu (2019)
Importan ce of Solid L ipid Nanoparti
Non-pegylated liposome-encapsulated doxorubicin citrate plus cyclophosphamide or vinorelbine in metastatic breast cancer not previously treated with chemotherapy:a multicenter phase III study.
V. Lorusso (2014)
Synthesis of a new nanoparticle system based on electrostatic alginate‐piperazine interactions
J. M. Román (2016)
Cyanine dyes in optical imaging of tumours.
Chunmeng Shi (2010)
Biodegradable m-PEG/PCL Core-Shell Micelles: Preparation and Characterization as a Sustained Release Formulation for Curcumin.
H. Danafar (2014)
Polyhedral Oligomeric Silsesquioxanes-Containing Conjugated Polymer Loaded PLGA Nanoparticles with Trastuzumab (Herceptin) Functionalization for HER2-Positive Cancer Cell Detection
K. Li (2011)
Plugging into proteins: poisoning protein function by a hydrophobic nanoparticle.
Guanghong Zuo (2010)
Nanotechnology applications in urology: a review
M. Maddox (2014)
The cytotoxicity of CdTe quantum dots and the relative contributions from released cadmium ions and nanoparticle properties.
Yuanyuan Su (2010)
Uniform hollow mesoporous silica nanocages for drug delivery in vitro and in vivo for liver cancer therapy
Ting-ting Wang (2011)
Polymer-Modified Nanoparticles as Targeted MR Imaging Agents
Stephen G. Boyes (2012)See more